Related Experiment Video
Updated: Jun 23, 2025
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Prevention of Brain Metastases: A New Frontier
Alessia Pellerino1, Tara Marie Davidson2, Shreyas S Bellur3
1Division of Neuro-Oncology, Department of Neuroscience 'Rita Levi Montalcini', University and City of Health and Science Hospital, 10126 Turin, Italy.
Abstract:
This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the risk of brain metastasis is related to disease status and molecular subtype (i.e., EGFR-mutant non-small cell lung cancer, HER2-positive and triple-negative breast cancer, BRAF and NRAF-mutant melanoma). Prophylactic cranial irradiation is the standard of care in patients in small cell lung cancer responsive to chemotherapy but at the price of late neurocognitive decline. More recently, several molecular agents with the capability to target molecular alterations driving tumor growth have proven as effective in the prevention of secondary relapse into the brain in clinical trials. This is the case for EGFR-mutant or ALK-rearranged non-small cell lung cancer inhibitors, tucatinib and trastuzumab-deruxtecan for HER2-positive breast cancer and BRAF inhibitors for melanoma. The need for screening with an MRI in asymptomatic patients at risk of brain metastases is emphasized.
Insights
Preventing brain metastases in lung cancer, breast cancer, and melanoma involves targeted therapies and, in some cases, prophylactic cranial irradiation. Molecular agents show promise in reducing secondary brain relapses, highlighting the need for MRI screening in high-risk patients.
Area of Science:
- Oncology
- Neuro-oncology
- Cancer Metastasis Research
Background:
- Brain metastases are a frequent complication of common solid tumors like lung cancer, breast cancer, and melanoma.
- Risk stratification for brain metastasis is influenced by disease status and specific molecular subtypes (e.g., EGFR-mutant NSCLC, HER2+ breast cancer, BRAF-mutant melanoma).
Purpose of the Study:
- To review current strategies for preventing brain metastases in prevalent solid tumors.
- To discuss the evolving role of molecularly targeted agents in reducing brain relapse.
- To emphasize the importance of screening for brain metastases in at-risk individuals.
Main Methods:
- Review of existing literature on brain metastasis prevention strategies.
- Analysis of clinical trial data for molecular agents targeting specific cancer subtypes.
- Discussion of prophylactic cranial irradiation and its associated neurocognitive effects.
Main Results:
- Prophylactic cranial irradiation is standard for small cell lung cancer but causes neurocognitive decline.
- Molecular agents (e.g., EGFR/ALK inhibitors, tucatinib, trastuzumab-deruxtecan, BRAF inhibitors) demonstrate efficacy in preventing brain relapse for specific subtypes.
- MRI screening is crucial for asymptomatic patients at high risk of brain metastases.
Conclusions:
- Targeted therapies are emerging as effective tools for preventing brain metastases in specific cancer types.
- Balancing treatment efficacy with neurocognitive side effects is essential.
- Systematic screening with MRI is recommended for early detection in at-risk populations.
